Agenus Inks Partnership Agreement With Zydus Lifesciences To Accelerate Clinical Development, Scale Global Manufacturing, And Expand Patient Access To Botensilimab And Balstilimab For Upfront Consideration Of $75M; Agenus To Receive Up To An Addit...

-3.12%

Agenus Inc.

AGEN

0.00

Agenus will also grant Zydus an exclusive license to develop and commercialize BOT and BAL in India and Sri Lanka, capitalizing on Zydus' established local market presence and infrastructure. Zydus will pay Agenus a 5 percent royalty on net sales in those countries.
In a demonstration of mutual commitment, Zydus will also make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares of common stock at $7.50 per share, totaling approximately $16 million in gross proceeds. Agenus intends to apply the net proceeds from the sale of the purchased shares for working capital and general corporate purposes, and will accelerate ongoing clinical development, registration and potential commercialization of BOT/BAL.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

BTIG Reiterates Buy on Akebia Therapeutics, Maintains $5 Price Target

Jasper Stock Jumps After Promising New Asthma Study Results

Black Diamond Therapeutics To Present Results From Phase 2 Clinical Study Of Silevertinib On Dec. 3

Incyte EVP & Chief Medical Officer Steven H. Stein Reports Disposal of Common Shares

Revelation Biosciences Prepares Gemini for Late-Stage Acute Kidney Injury Trials

Has Arcutis’ 106% 2025 Surge Outrun Its DCF Value and Sales Multiple?

Option Signals | Trump Goes All In on Robotics! Tesla Calls Jump 4x; Microsoft Options Volume Doubles

Royalty Pharma Signs $275 Million Royalty Agreement with Denali Therapeutics